Apremilast

Apremilast
Product Description

Indicated in Psoriatic Arthritis, Psoriasis and Oral Ulcers Associated with Behçet’s Disease

OMGENE LIFE SCIENCES PRIVATE LIMITED

  • IN
  • 2020
    On CPHI since
  • 50 - 99
    Employees
Company types
Pharmaceutical company
Specifications
  • CAS Registry Number
    608141-41-9

OMGENE LIFE SCIENCES PRIVATE LIMITED

  • IN
  • 2020
    On CPHI since
  • 50 - 99
    Employees
Company types
Pharmaceutical company

More Products from OMGENE LIFE SCIENCES PRIVATE LIMITED (44)

  • Omadacycline

    Product Omadacycline

    A tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms (1): Community-acquired bacterial pneumonia (CABP) (1.1); Acute bacterial skin and skin structure infections (ABSSSI) 
  • Semaglutide

    Product Semaglutide

    Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ,  to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and est...
  • Rezafungin

    Product Rezafungin

    Rezafungin is a next-generation, semi-synthetic, cyclic lipopeptide and echinocandin derivative, with potential antifungal activity. 
  • Tirzepatide

    Product Tirzepatide

    Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 

  • Cetrorelix  Acetate

    Product Cetrorelix Acetate

    Indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
  • Degarelix Acetate

    Product Degarelix Acetate

    Indicated for treatment of patients with advanced prostate cancer.
  • Bedaquiline Fumarate

    Product Bedaquiline Fumarate

    Diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB).
  • Binimetinib

    Product Binimetinib

    Indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
  • Brivaracetam

    Product Brivaracetam

    Indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
  • Carbetocin

    Product Carbetocin

    Used to prevent excessive bleeding after childbirth, particularly following Cesarean section.
  • Crisaborole

    Product Crisaborole

    Indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
  • Deutetrabenazine

    Product Deutetrabenazine

    Indicated for the treatment of chorea associated with Huntington’s disease, tardive dyskinesia in adults.

OMGENE LIFE SCIENCES PRIVATE LIMITED resources (1)